SEC Form 4 · accession 0001171843-17-003124
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sherrington Robin
Officer — SVP Bus. & Corp. Development
Period of report
May 12, 2017
Accepted (ET)
May 16, 2017 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | May 12, 2017 | M | 2,057 | $3.21 | A | 6,079 | D | |
| Common SharesF2 | May 12, 2017 | F | 1,345 | $4.18 | D | 4,734 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $3.21 | May 12, 2017 | M | 2,057 | D | — | May 18, 2017 | Common Shares | 2,057 | 0 | D |
Explanation of responses
- F1The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- F2Represents the closing price of the Company's common shares on May 11, 2017, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- F3The shares subject to the option fully vested on December 31, 2010.